awmsg logo



atorvastatin (Lipitor®)


Reference No. 1480

Publication date:
19/06/2012


Last review date:
30/08/2016

Appraisal information

atorvastatin (Lipitor®) 5 mg chewable tablet
atorvastatin (Lipitor®) 10 mg chewable tablet
atorvastatin (Lipitor®) 20 mg chewable tablet
atorvastatin (Lipitor®) 40 mg chewable tablet


Company: Pfizer Ltd
BNF category: Cardiovascular system
NMG meeting date: 28/03/2012
AWMSG meeting date: 09/05/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1112
Ministerial ratification: 18/06/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Atorvastatin (Lipitor®) chewable tablets are recommended as an option for use within NHS Wales: • As an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other non-pharmacological measures is inadequate. • To reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. • For the prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download